IV 
118TH CONGRESS 
2D SESSION 
H. RES. 1285 
Condemning the pro-abortion policies of the Biden administration. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 7, 2024 
Mr. MORAN (for himself, Mr. SMITH of New Jersey, Mr. BIGGS, Mr. BANKS, 
Mr. DUNCAN, Mr. BABIN, Mr. GUEST, Mr. PALMER, Mr. FLEISCHMANN, 
Mr. MOONEY, Mrs. BICE, Mrs. MILLER of Illinois, Mr. GOSAR, Mr. 
WEBER of Texas, Ms. BOEBERT, Mr. PFLUGER, Mr. CRENSHAW, Mr. 
MOORE of Alabama, Mr. FULCHER, Mr. KUSTOFF, Mr. GOODEN of 
Texas, Mr. WEBSTER of Florida, Mr. MOOLENAAR, Mrs. LESKO, Mr. 
ADERHOLT, Mr. SESSIONS, Mr. AUSTIN SCOTT of Georgia, Mr. BILI-
RAKIS, Mrs. HARSHBARGER, Mr. CARTER of Texas, Mr. BURGESS, Mr. 
PENCE, Mr. HIGGINS of Louisiana, Mr. CLINE, Mr. CRANE, Mr. OGLES, 
Mr. SELF, Mr. HERN, Mr. DUNN of Florida, and Ms. FOXX) submitted 
the following resolution; which was referred to the Committee on Energy 
and Commerce 
RESOLUTION 
Condemning the pro-abortion policies of the Biden 
administration. 
Whereas in this resolution, the term ‘‘induced abortion’’— 
(1) means a procedure with the intent to deliberately 
end the life of the unborn child in their mother’s womb; 
and 
(2) excludes procedures for the management of 
intrauterine fetal death, spontaneous miscarriage, ectopic 
VerDate Sep 11 2014 
01:50 Jun 08, 2024
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR1285.IH
HR1285
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1285 IH 
pregnancy, fetal remains, and that are necessary to pre-
serve the life of a pregnant woman or girl; 
Whereas chemically induced abortion in the United States 
most commonly occurs through a two-drug process where 
the mother— 
(1) first takes mifepristone, a drug that blocks pro-
gesterone, a hormone that is necessary for a baby devel-
oping in the womb; and 
(2) later takes misoprostol, a drug that causes the 
uterus to contract, evacuating the baby and the other 
contents; 
Whereas when the Commissioner of Food and Drugs initially 
approved mifepristone in 2000, they exceeded their statu-
tory authority, claimed pregnancy was a life-threatening 
illness in order to fast-track approval of the drug and 
jeopardized the health and safety of women and girls; 
Whereas the Commissioner of Food and Drugs failed to 
study the effects of the drug on minors, as required by 
Federal law, and failed to study the safety of the drug 
under the labeled conditions of use; 
Whereas mifepristone can cause complications, including life- 
threatening hemorrhaging, infection, incomplete induced 
abortions that require the need for emergency surgery, 
and mental health issues; 
Whereas, according to the Food and Drug Administration’s 
own label for mifepristone, roughly one in twenty-five 
women will end up in the emergency room after taking 
these drugs; 
Whereas the Commissioner of Food and Drugs issued a risk 
evaluation and mitigation strategy (in this preamble re-
ferred to as a ‘‘REMS’’) under section 505–1 of the Fed-
VerDate Sep 11 2014 
01:50 Jun 08, 2024
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR1285.IH
HR1285
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1285 IH 
eral Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) to 
attempt to mitigate the risks mifepristone poses to the 
health of women and girls; 
Whereas the initial safety requirements issued by the Com-
missioner of Food and Drugs when administering 
mifepristone— 
(1) limited the indicated use of the drug to seven 
weeks gestation; 
(2) required at least three in-person doctor visits; 
(3) ensured in-person dispensing; and 
(4) required providers to report the occurrence of 
adverse events; 
Whereas adverse events are defined in section 604–3 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 364) 
as any health-related event associated with the use of a 
cosmetic product that is adverse; 
Whereas in 2016, the Commissioner of Food and Drugs 
issued an updated REMS for mifepristone that aban-
doned many of the initial safety requirements; 
Whereas the Commissioner of Food and Drugs also removed 
the requirement for prescribers to report non-lethal ad-
verse events resulting in incomplete data collection to 
monitor complications from mifepristone; 
Whereas in the 2016 updated REMS, the Commissioner of 
Food and Drugs— 
(1) 
increased 
the 
gestation 
period 
where 
mifepristone may be taken from 7 weeks to 10 weeks; 
(2) permitted non-physicians, who have less training 
in handling complications from mifepristone, to prescribe 
mifepristone; and 
VerDate Sep 11 2014 
01:50 Jun 08, 2024
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR1285.IH
HR1285
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1285 IH 
(3) decreased mandatory office visits for patients 
from three to one, including eliminating the in-person fol-
low-up examination that ensures a woman or girl has not 
suffered complications or retained fetal remains; 
Whereas the Commissioner of Food and Drugs eliminated 
prior requirements that prescribers report all serious 
complications from mifepristone; 
Whereas the Commissioner of Food and Drugs does not have 
access to national data for chemically induced abortions 
or for complications from abortions; 
Whereas the decision of the Commissioner of Food and 
Drugs to no longer require prescribers to report adverse 
events, other than death, further weakened the accurate 
data the Food and Drug Administration has access to; 
Whereas one study estimates that the Food and Drug Admin-
istration may be missing data on up to 95 percent of se-
rious adverse events; 
Whereas serious adverse events are defined in section 604– 
5 of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 364) as any adverse event that results in death, 
a life-threatening experience, inpatient hospitalization, a 
persistent or significant disability or incapacity, a con-
genital anomaly or birth defect, an infection, or signifi-
cant disfigurement (including serious and persistent rash-
es, second- or third-degree burns, significant hair loss, or 
persistent or significant alteration of appearance), other 
than as intended, under conditions of use that are cus-
tomary or usual or requires, based on reasonable medical 
judgment, a medical or surgical intervention to prevent 
such outcomes; 
VerDate Sep 11 2014 
01:50 Jun 08, 2024
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6300
E:\BILLS\HR1285.IH
HR1285
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1285 IH 
Whereas in 2021, based on incomplete and unreliable data, 
the Commissioner of Food and Drugs eliminated the last 
remaining in-person office visit that ensured women and 
girls do not have ectopic pregnancies or other life-threat-
ening conditions before taking mifepristone; 
Whereas the abandonment of these safeguards by the Com-
missioner of Food and Drugs has allowed for chemically 
induced abortions by mail and online; 
Whereas women and girls can now receive mifepristone with-
out ever seeing a practitioner and without any certainty 
that follow-up care is available for potentially life-threat-
ening complications; 
Whereas women and girls located far from medical care cen-
ters will suffer disproportionately because they may need 
to quickly access a hospital to receive emergency surgery, 
blood transfusion, or intravenous antibiotics, but are un-
able to access this care quickly; 
Whereas in 2023, the Commissioner of Food and Drugs ap-
proved an updated REMS for mifepristone that— 
(1) permanently removed the requirement that 
health care providers personally dispense mifepristone; 
and 
(2) allowed certified pharmacies from both physical 
locations and online retailers to dispense mifepristone; 
Whereas there are no age limits on prescribing mifepristone, 
nor do the REMS for mifepristone require parental con-
sent or notice, meaning these drugs can be sent through 
the mail to minors without the knowledge or consent of 
their parents; 
Whereas removing the in-person dispensing requirement has 
intensified health risks for women and girls by removing 
VerDate Sep 11 2014 
01:50 Jun 08, 2024
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6300
E:\BILLS\HR1285.IH
HR1285
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1285 IH 
the ability of practitioners to diagnose an ectopic preg-
nancy through an ultrasound, which is the key method of 
diagnosis; 
Whereas mifepristone has no effect on an embryo implanted 
outside the uterus, which could cause a woman or girl 
with an undiagnosed ectopic pregnancy, who has taken 
mifepristone, to believe she is no longer pregnant because 
the early symptoms of a ruptured ectopic pregnancy, 
such as heavy bleeding, mirror those of a chemically in-
duced abortion; 
Whereas in reality the woman or girl would be at risk of rup-
turing a fallopian tube, or another organ, leading to cata-
strophic hemorrhaging and maternal death; 
Whereas ectopic pregnancies occur in 1 out of every 50 preg-
nancies; 
Whereas removing the in-person dispensing requirement pre-
vents providers from determining the gestational age of 
a baby; 
Whereas more than one out of every three women or girls 
who take mifepristone during their second trimester will 
require surgery; 
Whereas removing the in-person dispensing requirement pre-
vents providers from administering RhoGAM to women 
or girls with Rh negative blood to prevent potentially 
fatal complications for a baby in a future pregnancy; 
Whereas removing the in-person dispensing requirement pre-
vents providers from screening for coercion, which can 
cause providers to be uncertain about whether the 
mifepristone is being taken by the woman or girl to 
whom it is being dispensed to and whether it is being 
taken willingly; 
VerDate Sep 11 2014 
01:50 Jun 08, 2024
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6300
E:\BILLS\HR1285.IH
HR1285
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1285 IH 
Whereas mifepristone has been used by domestic abusers to 
unknowingly drug pregnant women and girls and to kill 
unborn babies; 
Whereas mifepristone is also used by sex traffickers to coerce 
their victims into having an induced abortion without see-
ing a health care provider, which can be a key oppor-
tunity for the victims of sex trafficking to be identified 
and assisted: and 
Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) condemns the Commissioner of Food and 
Drugs for lessening patient safeguards around a 
dangerous drug; 
(2) finds that the announcement from the 
Biden administration, on January 3, 2023, that 
health care providers are no longer required to per-
sonally dispense mifepristone, endangers the health 
of women and girls and enables reproductive coer-
cion by human traffickers and domestic abusers; and 
(3) condemns the Biden administration for its 
pro-abortion policies that prioritize abortion busi-
nesses over the health and safety of women and 
girls. 
Æ 
VerDate Sep 11 2014 
01:50 Jun 08, 2024
Jkt 049200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\HR1285.IH
HR1285
kjohnson on DSK7ZCZBW3PROD with $$_JOB